Poxel S.A. in brief
Poxel S.A. is a listed company in the Biotechnology industry, based in France. Its last known market value was $22 M (January 2024); there is no current figure. In the year to December 2024 it had sales of $7 M and a net loss of $20 M. Its shares trade under the symbol POXEL.PA (EURONEXT).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Poxel S.A. timeline
- 2009
- 🏁· approximateIncorporated as Poxel
- 2015
- •Legal Entity Identifier issuedLEI 9695003OIX0T7NX72N26 registered.
Events of Poxel S.A. from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in France: #219 (Jan 2020) · #265 (Jan 2021) · #303 (Jan 2022) · #397 (Dec 2022) · #422 (Jul 2023) · #403 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -275.9%
- Operating margin
- -52.8%
- Return on equity
- —
- Liabilities / assets
- 494.5%
- Revenue growth
- +235.5%
- R&D / revenue
- 15.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $7M | +235.5% | $-4M | $-20M | -275.9% |
| Dec 2023 | $2M | — | $-31M | $-38M | -1772.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-10M | — | — | $-0.41 | — |
| Dec 2023 | $-15M | — | — | $-1.14 | — |
Annual results
- Revenue
- $7 M
- Operating income
- $-4 M
- Net income
- $-20 M
For year ending December-2024 · source: official annual report (ESEF)
Balance sheet
- Total assets
- $16 M
- Total liabilities
- $77 M
- Total equity
- $-61 M
As of December-2024
Poxel S.A. scorecard#
Passes 2 of the 4 checks that could be worked out. Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 2
- ✓Revenue grew in the newest year235.5%Revenue up 235.5% in fiscal 2024.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.41 vs -1.14Diluted EPS -0.41 in fiscal 2024 against -1.14 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 2
- ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2024.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median-52.8%-52.8% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Poxel S.A.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | -52.8% | -60.5% | |
| Net margin | -275.9% | -68.9% | |
| Revenue growth | 235.5% | 15.8% |
4of 6on the Piotroski tests of financial strength
- Net loss of $20 million.
- Shareholders' equity is negative: -$61 million.
Poxel S.A.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in EUR thousands; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 6,636+235%100% | 1,981+194%100% | 674−95.0%100% | 13,397+96.8%100% | 6,806—100% | |
| Cost of revenue | 2,943+48.6%44.3% | 1,980+195%99.9% | 672+1039%99.7% | 59—0.4% | 0—0.0% | |
| Gross profit | 3,693+369200%55.7% | 1.0−50.0%0.1% | 2.0−100.0%0.3% | 13,339+96.0%99.6% | 6,806—100% | |
| Research and development | 1,001−95.2%15.1% | 20,953+50.3%1058% | 13,940−49.3%2068% | 27,479−6.0%205% | 29,219—429% | |
| Operating income | −3,501—−52.8% | −28,764—−1452% | −21,890—−3248% | −22,463—−168% | −29,819—−438% | |
| Interest and finance income | 1,893+663%28.5% | 248+45.9%12.5% | 170−80.4%25.2% | 868−49.6%6.5% | 1,722—25.3% | |
| Interest expense and finance costs | 14,016+128%211% | 6,148−37.9%310% | 9,908+236%1470% | 2,950+70.8%22.0% | 1,727—25.4% | |
| Income before tax | −18,303—−276% | −35,088—−1771% | −31,396—−4658% | −23,760—−177% | −31,794—−467% | |
| Income tax | 2.00.0%0.0% | 2.00.0%0.1% | 2.00.0%0.3% | 2.0−94.4%0.0% | 36—0.5% | |
| Net income including minority interests | −18,305—−276% | −35,090—−1771% | −31,398—−4658% | −23,763—−177% | −31,831—−468% | |
| Earnings per share, basic | -0.38—— | -1.05—— | -1.08—— | -0.83—— | -1.16—— | |
| Earnings per share, diluted | -0.38—— | -1.05—— | -1.08—— | -0.83—— | -1.16—— | |
| Shares, weighted average (basic) | 48+42.3%— | 34+15.3%— | 29+1.5%— | 29+4.0%— | 28—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 3,656+56.2%24.5% | 2,341−82.1%48.5% | 13,058−59.6%37.6% | 32,287−19.7%58.8% | 40,203—61.8% | |
| Receivables | 4,616+1099%30.9% | 385−2.3%8.0% | 394+688%1.1% | 50−82.2%0.1% | 281—0.4% | |
| Current assets | 14,852+229%99.4% | 4,520−72.7%93.7% | 16,574−54.4%47.7% | 36,337−20.9%66.2% | 45,964—70.6% | |
| Property, plant and equipment | — | — | — | 1,716−22.8%3.1% | 2,224—3.4% | |
| Other intangible assets | 2.0−80.0%0.0% | 10−99.9%0.2% | 16,606−0.2%47.8% | 16,631−0.1%30.3% | 16,642—25.6% | |
| Non-current assets | 83−72.6%0.6% | 303−98.3%6.3% | 18,140−2.2%52.3% | 18,552−2.9%33.8% | 19,113—29.4% | |
| Total assets | 14,935+210%100% | 4,823−86.1%100% | 34,714−36.8%100% | 54,889−15.7%100% | 65,077—100% | |
| Current liabilities | 18,965+42.7%127% | 13,287−51.5%275% | 27,419+72.4%79.0% | 15,901−3.4%29.0% | 16,459—25.3% | |
| Non-current liabilities | 54,901+35.2%368% | 40,614+59.0%842% | 25,537−17.0%73.6% | 30,782+42.8%56.1% | 21,554—33.1% | |
| Total equity | −58,931—−395% | −49,078—−1018% | −18,241−322%−52.5% | 8,206−69.7%15.0% | 27,065—41.6% | |
| Total liabilities and equity | 14,935+210%100% | 4,823−86.1%100% | 34,714−36.8%100% | 54,889−15.7%100% | 65,077—100% | |
| Cash-flow statement | ||||||
| Share-based compensation | 79—1.2% | −448−116%−22.6% | 2,819−38.8%418% | 4,603+64.7%34.4% | 2,794—41.1% | |
| Cash from operating activities | −9,513—−143% | −13,978—−706% | −21,813—−3236% | −16,893—−126% | −25,749—−378% | |
| Capital expenditure | — | — | −11—−1.6% | −28—−0.2% | −235—−3.5% | |
| Intangible assets bought | — | — | −12—−1.8% | −21—−0.2% | −46—−0.7% | |
| Cash from investing activities | 92+124%1.4% | 41—2.1% | 0—0.0% | −42−181%−0.3% | 52—0.8% | |
| Cash from financing activities | 10,733+232%162% | 3,230+25.0%163% | 2,585−71.4%384% | 9,025−68.6%67.4% | 28,712—422% | |
| Exchange-rate effect on cash | 3.0—0.0% | −10—−0.5% | −1.0—−0.1% | −4.0—−0.0% | 0—0.0% | |
| Change in cash | 1,315—19.8% | −10,717—−541% | −19,229—−2853% | −7,915−362%−59.1% | 3,016—44.3% | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How Poxel S.A. compares in Biotechnology
- Revenue$7 M · higher than 39% of 647
- Net margin-275.9% · higher than 21% of 408
- Revenue growth235.5% · higher than 90% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Poxel S.A.🇫🇷 | $22 M | — | -275.9% | +235.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 15, 2026
Figures from Official annual report (ESEF), value.today research, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Poxel S.A.? Verify and update this profile — free
Show Poxel S.A.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.